<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">nnp</journal-id><journal-title-group><journal-title xml:lang="en">Neurology, Neuropsychiatry, Psychosomatics</journal-title><trans-title-group xml:lang="ru"><trans-title>Неврология, нейропсихиатрия, психосоматика</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2074-2711</issn><issn pub-type="epub">2310-1342</issn><publisher><publisher-name>"IMA-Press", LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14412/2074-2711-2019-4-141-146</article-id><article-id custom-type="elpub" pub-id-type="custom">nnp-1224</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>REVIEWS</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОБЗОРЫ</subject></subj-group></article-categories><title-group><article-title>Errors in the management of patients with Alzheimer's disease: analysis of problems and ways of their solution</article-title><trans-title-group xml:lang="ru"><trans-title>Ошибки в ведении пациентов с болезнью Альцгеймера: анализ проблем и пути их решения</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Емелин</surname><given-names>А. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Emelin</surname><given-names>A. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"/><bio xml:lang="en"/><email xlink:type="simple">emelinand@rambler.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Литвиненко</surname><given-names>И. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Litvinenko</surname><given-names>I. V.</given-names></name></name-alternatives><bio xml:lang="ru"/><bio xml:lang="en"/><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лобзин</surname><given-names>В. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Lobzin</surname><given-names>V. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"/><bio xml:lang="en"/><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБВОУ ВО «Военно-медицинская академия им. С.М. Кирова» Минобороны России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>S.M. Kirov Military Medical Academy, Ministry of Defense of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>08</day><month>12</month><year>2019</year></pub-date><volume>11</volume><issue>4</issue><fpage>141</fpage><lpage>146</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Emelin A.Y., Litvinenko I.V., Lobzin V.Y., 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="ru">Емелин А.Ю., Литвиненко И.В., Лобзин В.Ю.</copyright-holder><copyright-holder xml:lang="en">Emelin A.Y., Litvinenko I.V., Lobzin V.Y.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://nnp.ima-press.net/nnp/article/view/1224">https://nnp.ima-press.net/nnp/article/view/1224</self-uri><abstract><p>Epidemiological data show that Alzheimer's disease (AD) is the most common cause of acquired cognitive impairment (CI). At the same time, according to statistics, vascular CI and vascular dementia predominate in Russia, which is mainly due to imperfect diagnosis, when any pathological condition associated with cerebral dysfunction in a patient with vascular risk factors is interpreted as dyscirculatory encephalopathy or chronic brain ischemia. However, this can be asthenoneurotic syndrome, migraine, vestibular dysfunction, and a number of neurodegenerative diseases, the most common condition of which is certainly AD. What is more, the treatment of age-related diseases, with the exception of acute vascular disease, is receiving manifestly inadequate attention. All this leads to the lack of a unified methodology for the management of these patients, to the impossibility to have adequate primary medical care, to the low detection rate of CI, to the prescription of drugs without appropriate indications, and to the denial of psychological correction methods. The review highlights the challenges facing the management of patients with AD and the possible ways of their solution.</p></abstract><trans-abstract xml:lang="ru"><p>Согласно эпидемиологическим данным, болезнь Альцгеймера (БА) – самая частая причина приобретенных когнитивных нарушений (КН). Вместе с тем в России, по статистическим данным, преобладают сосудистые КН и сосудистая деменция, что обусловлено главным образом несовершенством диагностики, когда любое патологическое состояние, связанное с церебральной дисфункцией у пациента, имеющего сосудистые факторы риска, трактуется как «дисциркуляторная энцефалопатия» или «хроническая ишемия мозга». Однако это могут быть астеноневротический синдром, мигрень, вестибулярная дисфункция и ряд нейродегенеративных заболеваний, самым частым из которых, безусловно, является БА. К тому же лечению заболеваний, ассоциированных с возрастом, за исключением острой сосудистой патологии, уделяется явно недостаточно внимания. Все это приводит к отсутствию единой методологии ведения таких пациентов, невозможности получения ими адекватной первичной врачебной помощи, низкой выявляемости КН, назначению лекарственных средств без соответствующих показаний, отказу от психологических методов коррекции. В обзоре освещены основные проблемы ведения пациентов с БА и возможные пути их решения.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>болезнь Альцгеймера</kwd><kwd>сосудистая деменция</kwd><kwd>когнитивно-поведенческая терапия</kwd><kwd>мемантин</kwd><kwd>психологические методы лечения</kwd></kwd-group><kwd-group xml:lang="en"><kwd>Alzheimer's disease</kwd><kwd>vascular dementia</kwd><kwd>cognitive behavioral therapy</kwd><kwd>memantine</kwd><kwd>psychological treatments</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Публикация статьи поддержана ООО «Мерц Фарма».</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Доклад ВОЗ. Деменция: приоритет общественного здравоохранения. 2013; www.who.int.</mixed-citation><mixed-citation xml:lang="en">Доклад ВОЗ. Деменция: приоритет общественного здравоохранения. 2013; www.who.int.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Литвиненко ИВ, Емелин АЮ, Лобзин ВЮ, Колмакова КА. Нейровизуализационные методы диагностики болезни Альцгеймера и цереброваскулярных заболеваний, сопровождающихся когнитивными нарушениями. Неврология, нейропсихиатрия, психосоматика. 2019;11(3S):18-25. doi: 10.14412/2074-2711-2019-3S-18-25</mixed-citation><mixed-citation xml:lang="en">Litvinenko IV, Emelin AYu, Lobzin VYu, Kolmakova KA. Neuroimaging techniques for diagnosing Alzheimer’s disease and cerebrovascular diseases with cognitive impairment. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2019;11(3S):18-25. (In Russ.) doi: 10.14412/2074-2711-2019-3S-18-25</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Лобзин ВЮ. Комплексная ранняя диагностика нарушений когнитивных функций. Журнал неврологии и психиатрии им. С.С. Корсакова. 2015;115(11):72-9.</mixed-citation><mixed-citation xml:lang="en">Lobzin VYu. Comprehensive early diagnosis of cognitive impairment. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2015;115(11):72-9. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Емелин АЮ, Лобзин ВЮ. Комплексная дифференциальная диагностика когнитивных нарушений. Журнал неврологии и психиатрии имени С.С. Корсакова. 2017;117 (6-2):33-9.</mixed-citation><mixed-citation xml:lang="en">Emelin AYu, Lobzin VYu. Complex differential diagnosis of cognitive disorders. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2017;117(6-2):33-9. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Petersen RC, Lopez O, Armstrong MJ, et al. Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018 Jan 16; 90(3):126-135. doi: 10.1212/WNL.0000000000004826. Epub 2017 Dec 27.</mixed-citation><mixed-citation xml:lang="en">Petersen RC, Lopez O, Armstrong MJ, et al. Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018 Jan 16; 90(3):126-135. doi: 10.1212/WNL.0000000000004826. Epub 2017 Dec 27.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Petersen R, Thomas R, Grundman M, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med. 2005 Jun 9;352(23):2379-88. Epub 2005 Apr 13.</mixed-citation><mixed-citation xml:lang="en">Petersen R, Thomas R, Grundman M, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med. 2005 Jun 9;352(23):2379-88. Epub 2005 Apr 13.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Feldman H, Ferris S, Winblad B, et al. Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. Lancet Neurol. 2007 Jun;6(6):501-12.</mixed-citation><mixed-citation xml:lang="en">Feldman H, Ferris S, Winblad B, et al. Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. Lancet Neurol. 2007 Jun;6(6):501-12.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Abbott RD, White RD, Ross GW, et al. Walking and dementia in physically capable elderly men. JAMA. 2004 Sep 22;292(12):1447-53.</mixed-citation><mixed-citation xml:lang="en">Abbott RD, White RD, Ross GW, et al. Walking and dementia in physically capable elderly men. JAMA. 2004 Sep 22;292(12):1447-53.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Scrameas N, Stern Y, Tang MX, et al. Mediterranean diet and risk for Alzheimer`s disease. Ann Neurol. 2006 Jun;59(6):877-9.</mixed-citation><mixed-citation xml:lang="en">Scrameas N, Stern Y, Tang MX, et al. Mediterranean diet and risk for Alzheimer`s disease. Ann Neurol. 2006 Jun;59(6):877-9.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Kramer A, Bherer L, Colcombe S, et al. Environmental influences on cognitive and brain plasticity during aging. J Gerontol A Biol Sci Med Sci. 2004 Sep;59(9):M940-57.</mixed-citation><mixed-citation xml:lang="en">Kramer A, Bherer L, Colcombe S, et al. Environmental influences on cognitive and brain plasticity during aging. J Gerontol A Biol Sci Med Sci. 2004 Sep;59(9):M940-57.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Kivipelto M, Solomon A, Ahtiluoto S, et al. The Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER): study design and progress. Alzheimers Dement. 2013 Nov;9(6):657-65. doi: 10.1016/j.jalz.2012.09.012. Epub 2013 Jan 17.</mixed-citation><mixed-citation xml:lang="en">Kivipelto M, Solomon A, Ahtiluoto S, et al. The Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER): study design and progress. Alzheimers Dement. 2013 Nov;9(6):657-65. doi: 10.1016/j.jalz.2012.09.012. Epub 2013 Jan 17.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Hö rder H, Johansson L, Guo X, et al. Midlife cardiovascular fitness and dementia: A 44-year longitudinal population study in women. Neurology. 2018 Apr 10;90(15):e1298-e1305. doi: 10.1212/WNL.0000000000005290. Epub 2018 Mar 14.</mixed-citation><mixed-citation xml:lang="en">Hö rder H, Johansson L, Guo X, et al. Midlife cardiovascular fitness and dementia: A 44-year longitudinal population study in women. Neurology. 2018 Apr 10;90(15):e1298-e1305. doi: 10.1212/WNL.0000000000005290. Epub 2018 Mar 14.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Емелин АЮ, Лобзин ВЮ, Воробьев СВ, редакторы. Когнитивные нарушения: руководство для врачей. Москва; 2019. 416 с.</mixed-citation><mixed-citation xml:lang="en">Emelin AYu, Lobzin VYu, Vorob'ev SV, editors. Kognitivnye narusheniya: rukovodstvo dlya vrachei [Cognitive impairment: a guide for doctors]. Moscow; 2019. 416 p.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Антоненко ЛМ, Парфенов ВА. Когнитивные и эмоциональные нарушения в среднем возрасте: вопросы диагностики и лечения. Медицинский совет. 2015;(10):22-7.</mixed-citation><mixed-citation xml:lang="en">Antonenko LM, Parfenov VA. Cognitive and emotional disorders in middle age: diagnosis and treatment. Meditsinskii sovet. 2015;(10): 22-7. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Chapman N, Huxley R, Anderson C, et al. Effects of a Perindopril-Based Blood PressureLowering Regimen on the Risk of Recurrent Stroke According to Stroke Subtype and Medical History. The PROGRESS Trial. Stroke. 2004 Jan;35(1):116-21. Epub 2003 Dec 11.</mixed-citation><mixed-citation xml:lang="en">Chapman N, Huxley R, Anderson C, et al. Effects of a Perindopril-Based Blood PressureLowering Regimen on the Risk of Recurrent Stroke According to Stroke Subtype and Medical History. The PROGRESS Trial. Stroke. 2004 Jan;35(1):116-21. Epub 2003 Dec 11.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Etgen T, Sander D, Bickel H. Mild Cognitive Impairment and Dementia. The Importance of Modifiable Risk Factors. Dtsch Arztebl Int. 2011 Nov;108(44):743-50. doi: 10.3238/arztebl.2011.0743. Epub 2011 Nov 4.</mixed-citation><mixed-citation xml:lang="en">Etgen T, Sander D, Bickel H. Mild Cognitive Impairment and Dementia. The Importance of Modifiable Risk Factors. Dtsch Arztebl Int. 2011 Nov;108(44):743-50. doi: 10.3238/arztebl.2011.0743. Epub 2011 Nov 4.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Forette F, Seux ML, Staessen J, et al. Prevention of dementia in randomised doubleblind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet. 1998 Oct 24; 352(9137):1347-51.</mixed-citation><mixed-citation xml:lang="en">Forette F, Seux ML, Staessen J, et al. Prevention of dementia in randomised doubleblind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet. 1998 Oct 24; 352(9137):1347-51.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Loef M, Walach H. Fruit, vegetables and prevention of cognitive decline or dementia: a systematic review of cohort studies. J Nutr Health Aging. 2012 Jul;16(7):626-30.</mixed-citation><mixed-citation xml:lang="en">Loef M, Walach H. Fruit, vegetables and prevention of cognitive decline or dementia: a systematic review of cohort studies. J Nutr Health Aging. 2012 Jul;16(7):626-30.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Larouche E, Hudon C, Goulet S. Mindfulness mechanisms and psychological effects for aMCI patients: A comparison with psychoeducation. Complement Ther Clin Pract. 2019 Feb;34:93-104. doi: 10.1016/j.ctcp.2018.11.008. Epub 2018 Nov 12.</mixed-citation><mixed-citation xml:lang="en">Larouche E, Hudon C, Goulet S. Mindfulness mechanisms and psychological effects for aMCI patients: A comparison with psychoeducation. Complement Ther Clin Pract. 2019 Feb;34:93-104. doi: 10.1016/j.ctcp.2018.11.008. Epub 2018 Nov 12.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Woods B, O'Philbin L, Farrell EM, et al. Reminiscence therapy for dementia. Cochrane Database Syst Rev. 2018 Mar 1;3:CD001120. doi: 10.1002/14651858.CD001120.pub3.</mixed-citation><mixed-citation xml:lang="en">Woods B, O'Philbin L, Farrell EM, et al. Reminiscence therapy for dementia. Cochrane Database Syst Rev. 2018 Mar 1;3:CD001120. doi: 10.1002/14651858.CD001120.pub3.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">O'Brien JT, Holmes C, Jones M, et al. Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the British Association for Psychopharmacology. J Psychopharmacol. 2017 Feb;31(2):147-168. doi: 10.1177/0269881116680924. Epub 2017 Jan 20.</mixed-citation><mixed-citation xml:lang="en">O'Brien JT, Holmes C, Jones M, et al. Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the British Association for Psychopharmacology. J Psychopharmacol. 2017 Feb;31(2):147-168. doi: 10.1177/0269881116680924. Epub 2017 Jan 20.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Парфенов ВА. Лечение постинсультных когнитивных нарушений. Применение Омарона. Русский медицинский журнал. Неврология. 2010;18(16):986-90.</mixed-citation><mixed-citation xml:lang="en">Parfenov VA. Treatment of post-stroke cognitive impairment. The use Of Omaron. Russkii meditsinskii zhkrnal. Nevrologiya. 2010;18(16): 986-90. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Приказ МЗ РФ от 20.12.2012 г. №1228н «Об утверждении стандарта специализированной медицинской помощи при болезни Альцгеймера».</mixed-citation><mixed-citation xml:lang="en">Order of the Ministry of health of the Russian Federation of 20.12.2012 №1228n гon approval of the standard of specialized medical care for Alzheimer's diseaseх.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Winblad B, Fioravanti M, Dolezal T, et al. Therapeutic use of nicergoline. Clin Drug Investig. 2008;28(9):533-52.</mixed-citation><mixed-citation xml:lang="en">Winblad B, Fioravanti M, Dolezal T, et al. Therapeutic use of nicergoline. Clin Drug Investig. 2008;28(9):533-52.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Smith E, Cieslak A, Barber P, et al. Therapeutic Strategies and Drug Development for Vascular Cognitive Impairment. J Am Heart Assoc. 2017 May 5;6(5). pii: e005568. doi: 10.1161/JAHA.117.005568.</mixed-citation><mixed-citation xml:lang="en">Smith E, Cieslak A, Barber P, et al. Therapeutic Strategies and Drug Development for Vascular Cognitive Impairment. J Am Heart Assoc. 2017 May 5;6(5). pii: e005568. doi: 10.1161/JAHA.117.005568.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Fioravanti M, Flicker L. Efficacy of nicergoline in dementia and other age associated forms of cognitive impairment. Cochrane Database Syst Rev. 2001;(4):CD003159.</mixed-citation><mixed-citation xml:lang="en">Fioravanti M, Flicker L. Efficacy of nicergoline in dementia and other age associated forms of cognitive impairment. Cochrane Database Syst Rev. 2001;(4):CD003159.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Szatmari SZ, Whitehouse PJ. Vinpocetine for cognitive impairment and dementia. Cochrane Database Syst Rev. 2003;(1): CD003119.</mixed-citation><mixed-citation xml:lang="en">Szatmari SZ, Whitehouse PJ. Vinpocetine for cognitive impairment and dementia. Cochrane Database Syst Rev. 2003;(1): CD003119.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Im JJ, Jeong HS, Park JS, et al. Changes in Regional Cerebral Perfusion after Nicergoline Treatment in Early Alzheimer's Disease: A Pilot Study. Dement Neurocogn Disord. 2017 Dec; 16(4):104-109. doi: 10.12779/dnd.2017.16.4.104. Epub 2017 Dec 31.</mixed-citation><mixed-citation xml:lang="en">Im JJ, Jeong HS, Park JS, et al. Changes in Regional Cerebral Perfusion after Nicergoline Treatment in Early Alzheimer's Disease: A Pilot Study. Dement Neurocogn Disord. 2017 Dec; 16(4):104-109. doi: 10.12779/dnd.2017.16.4.104. Epub 2017 Dec 31.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Голенков АВ, Малышкина ЮН, Сподина ЕА, Ундеров ДА. Ошибки в диагностике и лечении болезни Альцгеймера. Вестник Чувашского университета. 2013;(3):397-401.</mixed-citation><mixed-citation xml:lang="en">Golenkov AV, Malyshkina YuN, Spodina EA, Underov DA. Errors in the diagnosis and treatment of Alzheimer's disease. Vestnik Chuvashskogo universiteta. 2013;(3):397-401. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Small G, Dubois B. A review of compliance to treatment in Alzheimer's disease: potential benefits of a transdermal patch. Curr Med Res Opin. 2007 Nov;23(11):2705-13.</mixed-citation><mixed-citation xml:lang="en">Small G, Dubois B. A review of compliance to treatment in Alzheimer's disease: potential benefits of a transdermal patch. Curr Med Res Opin. 2007 Nov;23(11):2705-13.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Matsunaga S, Kishi T, Iwata N. Memantine monotherapy for Alzheimer's disease: a systematic review and meta-analysis. PLoS One. 2015 Apr 10;10(4):e0123289. doi: 10.1371/journal.pone.0123289. eCollection 2015.</mixed-citation><mixed-citation xml:lang="en">Matsunaga S, Kishi T, Iwata N. Memantine monotherapy for Alzheimer's disease: a systematic review and meta-analysis. PLoS One. 2015 Apr 10;10(4):e0123289. doi: 10.1371/journal.pone.0123289. eCollection 2015.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Schmidt R, Hofer E, Bouwman J. EFNSENS/EAN Guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer's disease. Eur J Neurol. 2015 Jun;22(6):889-98. doi: 10.1111/ene.12707. Epub 2015 Mar 25.</mixed-citation><mixed-citation xml:lang="en">Schmidt R, Hofer E, Bouwman J. EFNSENS/EAN Guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer's disease. Eur J Neurol. 2015 Jun;22(6):889-98. doi: 10.1111/ene.12707. Epub 2015 Mar 25.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Литвиненко ИВ, Наумов КМ, Одинак ММ. Коррекция когнитивных и некогнитивных симптомов цереброваскулярной болезни. Журнал неврологии и психиатрии им. C.C. Корсакова. 2014;114(4):35–40.</mixed-citation><mixed-citation xml:lang="en">Litvinenko IV, Naumov KM, Odinak MM. Correction of cognitive and non-cognitive symptoms of cerebrovascular disease. Zhurnal nevrologii i psikhiatrii im. C.C. Korsakova. 2014;114(4):35–40. (In Russ.)</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
